Clinical Trial Detail

NCT ID NCT03667716
Title COM701 in Subjects With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Compugen Ltd
Indications

triple-receptor negative breast cancer

endometrial cancer

lung non-small cell carcinoma

Advanced Solid Tumor

ovarian cancer

Therapies

COM701

COM701 + Nivolumab

Age Groups: senior adult

No variant requirements are available.